Department of Pulmonary Medicine, Erasmus Medical Center, Rotterdam, Netherlands.
Erasmus Cancer Institute, Erasmus Medical Center, Rotterdam, Netherlands.
Front Immunol. 2018 Dec 3;9:2804. doi: 10.3389/fimmu.2018.02804. eCollection 2018.
Dendritic cell (DC) based cancer immunotherapy aims at the activation of the immune system, and in particular tumor-specific cytotoxic T lymphocytes (CTLs) to eradicate the tumor. DCs represent a heterogeneous cell population, including conventional DCs (cDCs), consisting of cDC1s, cDC2s, plasmacytoid DCs (pDCs), and monocyte-derived DCs (moDCs). These DC subsets differ both in ontogeny and functional properties, such as the capacity to induce CD4 and CD8 T-cell activation. MoDCs are most frequently used for vaccination purposes, based on technical aspects such as availability and expansion. However, whether moDCs are superior over other DC subsets in inducing anti-tumor immune responses, is unknown, and likely depends on tumor type and composition of the tumor microenvironment. In this review, we discuss cellular aspects essential for DC vaccination efficacy, and the most recent findings on different DC subsets that could be used for DC-based cancer immunotherapy. This can prove valuable for the future design of more effective DC vaccines by choosing different DC subsets, and sheds light on the working mechanism of DC immunotherapy.
树突状细胞（DC）为基础的癌症免疫疗法旨在激活免疫系统，特别是肿瘤特异性细胞毒性 T 淋巴细胞（CTL）以消灭肿瘤。树突状细胞是一个异质性的细胞群体，包括常规树突状细胞（cDC），包括 cDC1、cDC2、浆细胞样树突状细胞（pDC）和单核细胞衍生的树突状细胞（moDC）。这些树突状细胞亚群在发生和功能特性上存在差异，例如诱导 CD4 和 CD8 T 细胞激活的能力。moDC 最常用于疫苗接种，这是基于可用性和扩增等技术方面的考虑。然而，moDC 是否在诱导抗肿瘤免疫反应方面优于其他树突状细胞亚群尚不清楚，这可能取决于肿瘤类型和肿瘤微环境的组成。在这篇综述中，我们讨论了树突状细胞疫苗接种功效的细胞方面的重要性，以及不同树突状细胞亚群的最新发现，这些发现可能用于基于树突状细胞的癌症免疫疗法。这对于通过选择不同的树突状细胞亚群来设计更有效的树突状细胞疫苗具有重要意义，并揭示了树突状细胞免疫疗法的作用机制。
